NCT02631876 (Clinical Trial/ MIRVETUXIMAB SORAVTANSINE/ IMGN-853)

Study Title
PH2 Study of IMGN853 vs Investigator’s Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer NCT02631876

Trial Description
This is a Phase 2, open label, randomized study. Stage 1 is designed to select the dosing schedule for IMGN853. Stage 2 is designed to compare the efficacy of IMGN853 to that of selected standard of care chemotherapy (Investigator’s choice) in patients with FR-alpha positive advanced EOC, primary peritoneal cancer or fallopian tube cancer.

This trial is sponsored by ImmunoGen, Inc.®

Study Data

  • Condition: Fallopian tube Cancer
  • Interventions:
    • Drugs used in this trial
      • IMGN853
      • Paclitaxel
      • Doxorubicin
      • Gemcitabine
      • Topotecan
  • Phase: III
  • Enrollment: 333
  • Start: November 2016
  • Estimated Completion: February 2019
  • Last verified: February 2018
  • Last Updated: February 2018

Study Schematic

Click here to Return to Drug map


Last Editorial review: February 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.